C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
Sotirios Tsimikas, MD, FACC*,*,
James T. Willerson, MD, FACC and
Paul M. Ridker, MD, FACC
* Department of Medicine, Division of Cardiology, University of California, San Diego, San Diego, California
St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas
Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Manuscript received June 16, 2005;
revised manuscript received October 21, 2005,
accepted October 25, 2005.
* Reprint requests and correspondence: Dr. Sotirios Tsimikas, Vascular Medicine Program, University of California, San Diego, 9500 Gilman Drive, BSB 1080, La Jolla, California 92093-0682. (Email: stsimikas{at}ucsd.edu).
Several emerging plasma biomarkers may ultimately prove useful in risk stratification and prognosis of cardiovascular disease. The clinical utility of these biomarkers will depend on their ability to provide a reflection of the underlying atherosclerotic burden or activity; the ability to provide reliable, accurate, and cost-effective information; and the ability to predict future events. High-sensitivity C-reactive protein (hs-CRP) fulfills many, if not all, of these criteria, and blood levels of hs-CRP are now commonly used in clinical practice to improve vascular risk prediction in primary and secondary prevention across all levels of low-density lipoprotein-cholesterol (LDL-C), all levels of the Framingham Risk Score, and all levels of metabolic syndrome. High-sensitivity C-reactive protein may also have clinical relevance as an adjunct to LDL-C for both the targeting and monitoring of statin therapy. Accumulating evidence suggests that several other selected emerging biomarkers may also potentially prove useful in the diagnosis and prognosis of cardiovascular disease. Specifically, data are accumulating on the potential clinical utility of lipoprotein-associated lipoprotein-associated phospholipase A2, myeloperoxidase, oxidized LDL, lipoprotein (a), isoprostanes, and small, dense LDL. This review focuses on hs-CRP and these emerging plasma biomarkers, and their potential diagnostic and prognostic utility in cardiovascular disease. Plasma biomarkers that reflect the clinical potential of atherothrombotic disease may allow more precise risk stratification and prognostication in high-risk populations, and perhaps earlier diagnosis and intervention in patients at risk for or with occult cardiovascular disease.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | apo = apolipoprotein | | CAD = coronary artery disease | | CETP = cholesterol ester transfer protein | | ELISA = enzyme-linked immunoabsorbent assay | | HDL-C = high-density lipoprotein cholesterol | | HOCl = hypochlorous acid | | hs-CRP = high-sensitivity C-reactive protein | | LDL-C = low-density lipoprotein cholesterol | | Lp(a) = lipoprotein (a) | | Lp-PLA2 = lipoprotein-associated phospholipase A2 | | MPO = myeloperoxidase | | OR = odds ratio | | OxLDL = oxidized LDL | | OxPLs = oxidized phospholipids | | PAF-AH = platelet-activating factor acetylhydrolase | | PCI = percutaneous coronary intervention |
|
This article has been cited by other articles:
|
|
|
|
 
B. Zhang, A. Matsunaga, D. L. Rainwater, S.-i. Miura, K. Noda, H. Nishikawa, Y. Uehara, K. Shirai, M. Ogawa, and K. Saku
Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study
J. Lipid Res.,
September 1, 2009;
50(9):
1832 - 1841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Oeffinger, B. Adams-Huet, R. G. Victor, T. S. Church, P. G. Snell, A. L. Dunn, D. A. Eshelman-Kent, R. Ross, P. M. Janiszewski, A. J. Turoff, et al.
Insulin Resistance and Risk Factors for Cardiovascular Disease in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
August 1, 2009;
27(22):
3698 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Filep
Platelets Affect the Structure and Function of C-Reactive Protein
Circ. Res.,
July 17, 2009;
105(2):
109 - 111.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Iijima, R A Byrne, G Ndrepepa, S Braun, J Mehilli, P B Berger, A Schomig, and A Kastrati
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials
Heart,
January 15, 2009;
95(2):
107 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A Scott
Evaluating cardiovascular risk assessment for asymptomatic people
BMJ,
January 5, 2009;
338(jan05_1):
a2844 - a2844.
[Full Text]
|
|
|
|
|
|
|
M. F. Lopes-Virella, R. E. Carter, G. E. Gilbert, R. L. Klein, M. Jaffa, A. J. Jenkins, T. J. Lyons, W. T. Garvey, G. Virella, and and the DCCT/EDIC Cohort Study Group
Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications
Diabetes Care,
October 1, 2008;
31(10):
2006 - 2012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Jaffe
Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers
Clin. Chem.,
September 1, 2008;
54(9):
1432 - 1442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Ankle Brachial Index Collaboration
Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality: A Meta-analysis
JAMA,
July 9, 2008;
300(2):
197 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Povsic and P. J. Goldschmidt-Clermont
Review: Endothelial progenitor cells: markers of vascular reparative capacity
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
199 - 213.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. T. Papas, C. K. Maltezos, N. Papanas, G. Kopadis, J. Marakis, E. Maltezos, and E. Bastounis
High-Sensitivity CRP Is Correlated With Neurologic Symptoms and Plaque Instability in Patients With Severe Stenosis of the Carotid Bifurcation
Vascular and Endovascular Surgery,
June 1, 2008;
42(3):
249 - 255.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Nagaoka, L. Kuo, Y. Ren, A. Yoshida, and T. W. Hein
C-Reactive Protein Inhibits Endothelium-Dependent Nitric Oxide-Mediated Dilation of Retinal Arterioles via Enhanced Superoxide Production
Invest. Ophthalmol. Vis. Sci.,
May 1, 2008;
49(5):
2053 - 2060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Van Vre, H. Bult, V. Y. Hoymans, V. F.I. Van Tendeloo, C. J. Vrints, and J. M. Bosmans
Human C-Reactive Protein Activates Monocyte-Derived Dendritic Cells and Induces Dendritic Cell-Mediated T-Cell Activation
Arterioscler Thromb Vasc Biol,
March 1, 2008;
28(3):
511 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. S. Packard and P. Libby
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Clin. Chem.,
January 1, 2008;
54(1):
24 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Haugen, I. P. Casserly, J. G. Regensteiner, and W. R. Hiatt
Risk assessment in the patient with established peripheral arterial disease
Vascular Medicine,
November 1, 2007;
12(4):
343 - 350.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello
Role of Inflammation in Atherosclerosis
J. Nucl. Med.,
November 1, 2007;
48(11):
1800 - 1815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Philpott and T. J. Anderson
Reactive Hyperemia and Cardiovascular Risk
Arterioscler Thromb Vasc Biol,
October 1, 2007;
27(10):
2065 - 2067.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Schoenhagen
Plaque Temperature, Arterial Remodeling, and Inflammation: Understanding "Hot-Spots" in the Coronary Arteries
J. Am. Coll. Cardiol.,
June 12, 2007;
49(23):
2272 - 2273.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman
Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans
Circulation,
May 29, 2007;
115(21):
2715 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lavi, A. Prasad, E. H. Yang, V. Mathew, R. D. Simari, C. S. Rihal, L. O. Lerman, and A. Lerman
Smoking Is Associated With Epicardial Coronary Endothelial Dysfunction and Elevated White Blood Cell Count in Patients With Chest Pain and Early Coronary Artery Disease
Circulation,
May 22, 2007;
115(20):
2621 - 2627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Y.H. Lip, J. V. Patel, E. Hughes, and R. G. Hart
High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis
Stroke,
April 1, 2007;
38(4):
1229 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Revkin, C. L. Shear, H. G. Pouleur, S. W. Ryder, and D. G. Orloff
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
Pharmacol. Rev.,
March 1, 2007;
59(1):
40 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wang, K. S. L. Lam, E. W. Kraegen, G. Sweeney, J. Zhang, A. W.K. Tso, W.-S. Chow, N. M.S. Wat, J. Y. Xu, R. L.C. Hoo, et al.
Lipocalin-2 Is an Inflammatory Marker Closely Associated with Obesity, Insulin Resistance, and Hyperglycemia in Humans
Clin. Chem.,
January 1, 2007;
53(1):
34 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsimikas, M. Aikawa, F. J. Miller Jr, E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum
Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression
Arterioscler Thromb Vasc Biol,
January 1, 2007;
27(1):
175 - 181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Walley, A. I.F. Blakemore, and P. Froguel
Genetics of obesity and the prediction of risk for health
Hum. Mol. Genet.,
October 15, 2006;
15(suppl_2):
R124 - R130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
